MYCOF News and Press, New Age Brands From 04/03/23

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that it has improved its financial ...

2023-04-03 06:29:06 ET Mydecine Innovations Group ( OTCPK:MYCOF ) said it has improved its financial position, reduced cash burn, increased efficiencies and expanded its intellectual property (IP) portfolio. The company noted that is focusing on IP portfolio with novel molecu...

VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health wi...

2023-04-03 03:50:37 ET Mydecine Innovations Group press release ( OTCPK:MYCOF ): FY GAAP EPS of -$1.34. The company had $11.03K in cash and cash equivalents as of December 31, 2022; the company received $1.8M subsequently in early January 2023 from the sale of investments. ...

DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced debt set...

2023-03-06 07:49:55 ET Mydecine Innovations ( OTCPK:MYCOF ) announced share for debt settlements for debt owed to certain arms-length creditors, service providers and debtors of the company. Post the agreements, the debt will be converted into shares; debt settlements wer...

DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental...

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health. The company today announced, further to its Sept. 1 news release, it has closed the sale of all of...

DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address add...